BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 37417358)

  • 41. Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPα signaling in fibroblasts.
    Lee PJ; Sui YH; Liu TT; Tsang NM; Huang CH; Lin TY; Chang KP; Liu SC
    J Exp Clin Cancer Res; 2022 Aug; 41(1):254. PubMed ID: 35986369
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current Perspectives on Nasopharyngeal Carcinoma.
    Lee HM; Okuda KS; González FE; Patel V
    Adv Exp Med Biol; 2019; 1164():11-34. PubMed ID: 31576537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review.
    Xue F; He X
    Methods Mol Biol; 2020; 2204():99-107. PubMed ID: 32710318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Understanding the interplay between host immunity and Epstein-Barr virus in NPC patients.
    Shen Y; Zhang S; Sun R; Wu T; Qian J
    Emerg Microbes Infect; 2015 Mar; 4(3):e20. PubMed ID: 26038769
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advances in Research on microRNAs Related to the Invasion and Metastasis of Nasopharyngeal Carcinoma.
    Zhang S; Wang B; Zheng L; Fu Z; Fu Y; Huang W; Cheng A
    Curr Mol Pharmacol; 2022; 15(3):463-474. PubMed ID: 34126919
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vaccination as a therapeutic strategy for Nasopharyngeal carcinoma.
    Huang J; Harris E; Lorch J
    Oral Oncol; 2022 Dec; 135():106083. PubMed ID: 36332445
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy: A Randomized, Controlled Clinical Trial.
    Fu S; Li Y; Han Y; Wang H; Chen Y; Yan O; He Q; Ma H; Liu L; Liu F
    Int J Radiat Oncol Biol Phys; 2022 May; 113(1):101-113. PubMed ID: 35074433
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationship between pretreatment concentration of plasma Epstein-Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation.
    Peng L; Yang Y; Guo R; Mao YP; Xu C; Chen YP; Sun Y; Ma J; Tang LL
    Cancer Med; 2018 Dec; 7(12):5988-5998. PubMed ID: 30378277
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
    Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
    Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
    Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genetic variants in NKG2D axis and susceptibility to Epstein-Barr virus-induced nasopharyngeal carcinoma.
    Viet NH; Trung NQ; Dong LT; Trung LQ; Espinoza JL
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):713-723. PubMed ID: 33392659
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantitation of DNA methylation in Epstein-Barr virus-associated nasopharyngeal carcinoma by bisulfite amplicon sequencing.
    Zhao W; Mo Y; Wang S; Midorikawa K; Ma N; Hiraku Y; Oikawa S; Huang G; Zhang Z; Murata M; Takeuchi K
    BMC Cancer; 2017 Jul; 17(1):489. PubMed ID: 28716111
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of Plasma Epstein-Barr Virus LMP1 and EBER1 with Circulating Tumor Cells and the Metastasis of Nasopharyngeal Carcinoma.
    Sun L; Wang Y; Shi J; Zhu W; Wang X
    Pathol Oncol Res; 2020 Jul; 26(3):1893-1901. PubMed ID: 31832991
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.
    Chia WK; Teo M; Wang WW; Lee B; Ang SF; Tai WM; Chee CL; Ng J; Kan R; Lim WT; Tan SH; Ong WS; Cheung YB; Tan EH; Connolly JE; Gottschalk S; Toh HC
    Mol Ther; 2014 Jan; 22(1):132-9. PubMed ID: 24297049
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma.
    Tan LP; Tan GW; Sivanesan VM; Goh SL; Ng XJ; Lim CS; Kim WR; Mohidin TBBM; Mohd Dali NS; Ong SH; Wong CY; Sawali H; Yap YY; Hassan F; Pua KC; Koay CE; Ng CC; Khoo AS;
    Int J Cancer; 2020 Apr; 146(8):2336-2347. PubMed ID: 31469434
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of methylation status of Epstein-Barr virus DNA C promoter in the diagnosis of nasopharyngeal carcinoma.
    Zheng XH; Wang RZ; Li XZ; Zhou T; Zhang JB; Zhang PF; Lu LX; Jia WH
    Cancer Sci; 2020 Feb; 111(2):592-600. PubMed ID: 31834989
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.
    Lu T; Guo Q; Lin K; Chen H; Chen Y; Xu Y; Lin C; Su Y; Chen Y; Chen M; Zheng Y; Ye Y; Lin S; Zong J; Pan J
    Cancer Sci; 2020 May; 111(5):1711-1723. PubMed ID: 32155300
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of Epstein-Barr virus and human papillomavirus infection on macrophage migration inhibitory factor and macrophage polarization in nasopharyngeal carcinoma.
    Feng G; Xu Y; Ma N; Midorikawa K; Oikawa S; Kobayashi H; Nakamura S; Ishinaga H; Zhang Z; Huang G; Takeuchi K; Murata M
    BMC Cancer; 2021 Aug; 21(1):929. PubMed ID: 34407796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma.
    Peng L; Liu JQ; Chen YP; Ma J
    Br J Radiol; 2019 Oct; 92(1102):20181031. PubMed ID: 31112398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.